Reuters Television Report features NanoLogix Biotechnology and University of Texas Health Science Center Clinical Trial

Headline: “U.S. company says rapid diagnosis technology could save lives”

HUBBARD, Ohio--(BUSINESS WIRE)-- NanoLogix (PINK SHEETS: NNLX), an innovator in the accelerated detection and identification of live-cell microorganisms, announced today Reuters Television has featured the NanoLogix rapid diagnostic technology in its global business coverage.

The video can be viewed here:

Produced by Rob Muir, the report from Reuters features an interview with NanoLogix CEO Bret Barnhizer while the company was exhibiting at the American Society for Microbiology BioDefense and Emerging Diseases Research Meeting and Exhibition held in Washington, DC (February 7-9, 2011). The report includes an additional interview with Dr. Jonathan Faro of the University of Texas Health Science Center- Houston. Dr. Faro is currently leading a 300 patient trial utilizing NanoLogix BNP/BNF/Quick-Test technologies for rapid detection of Group B Streptococcus (GBS).

Group B Strep is one of the leading health threats for newborns. Current methods for detection and identification take 48 to 72+ hours for results. The new technology from NanoLogix enables detection, identification, and determination of antibiotic sensitivity in 6 hours or less.

NanoLogix will return to Washington DC April 19-21, 2011 for the Food Safety Summit, where the company's technology will be on exhibit. Additional information about the event can be found at

Joining NanoLogix at the Food Safety Summit will be John Tracy, who now serves the company in the position of General Operations Manager. Mr. Tracy brings 30 years of international technology management experience to NanoLogix from his career with both IBM and EMC.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Technica Communications for NanoLogix
Lisa Ann Pinkerton, 650-288-1824
[email protected]
NanoLogix, Inc.
Carol Surrena, 330-534-0800
[email protected]

KEYWORDS:   United States  North America  Ohio  Texas

INDUSTRY KEYWORDS:   Stem Cells  Surgery  Technology  Hardware  Practice Management  Health  Alternative Medicine  Biotechnology  Cardiology  Fitness & Nutrition  Hospitals  Oncology  Pharmaceutical  Other Health  Natural Resources  Agriculture  Professional Services  Finance  Legal  Research  Diabetes  FDA  Medical Supplies  Nursing  Veterinary  Science